Binder, David C.
Mayo Clinic
University of Colorado Cancer Center
Citations 2
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Benson, Al B. , D’Angelica, Michael I. , Ahmed, Aijaz, Akce, Mehmet , Anaya, Daniel A. , Are, Chandrakanth , Aye, Lydia, Baker, Marshall S., Binder, David C. , Burgoyne, Adam M. , Castellanos, Jason , Cloyd, Jordan M. , Franses, Joseph W. , Harris, William P., Iyer, Renuka , Jennings, Lawrence J. , Kelley, Robin Kate , Khan, Sajid , Palta, Manisha , Sahai, Vaibhav , Stein, Stacey , Stephans, Kevin L. , Thanikachalam, Kannan , Yano, Motoyo , Yopp, Adam C. , Zhao, Ken, Schonfeld, Ryan, Hochstetler, Cindy, Sahai, Vaibhav , Abrams, Thomas A. , Anders, Robert A. , Bachini, Melinda , Brown, Daniel B. , Cullinan, Darren R. , Glazer, Evan S. , Levine, Matthew H , Melstrom, Laleh , Raman, Steven S. , Ronnekleiv-Kelly, Sean M , Turk, Anita , Vauthey, Jean‐Nicolas , Venook, Alan P. , Zhao, Ken
Journal of the National Comprehensive Cancer Network | September 10, 2025 | Volume: 23 | Issue: 9 | Pages: 403-418
The NCCN Guidelines for Biliary Tract Cancers (BTCs) provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts is convened at least once annually to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. This manuscript focuses on the adjuvant chemotherapy and chemoradiation treatment options for BTCs as well as the systemic treatment recommendations for patients with advanced BTCs.
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
Benson, Al B. , D’Angelica, Michael I. , Abbott, Daniel E. , Ahmed, Aijaz, Anaya, Daniel A. , Are, Chandrakanth , Binder, David C. , Bowlus, Christopher L. , Burgoyne, Adam M. , Castellanos, Jason , Chahal, Prabhleen , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon , Jennings, Lawrence J. , Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Reddy, Sanjay S. , Sahai, Vaibhav , Singh, Gagandeep , Stein, Stacey , Yopp, Adam C. , McMillian, Nicole R., Schonfeld, Ryan, Hochstetler, Cindy, Bowlus, Christopher L , Sahai, Vaibhav , Abrams, Thomas A. , Anders, Robert A. , Bachini, Melinda , Borad, Mitesh J. , Brown, Daniel B. , Glazer, Evan S. , Hawkins, William G , Levine, Matthew H , Raman, Steven S. , Ronnekleiv-Kelly, Sean M , Turk, Anita , Vauthey, Jean‐Nicolas , Venook, Alan P.
Journal of the National Comprehensive Cancer Network | July 11, 2023 | Volume: 21 | Issue: 7 | Pages: 694-704
In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.